
Antibodiesinc/Cav3.2 Ca2+ channel/75-095/1 Ea
商品编号:
75-095
市场价:
¥0.00
美元价:
0.00
产品分类:
重组抗体
公司分类:
Recombinant_antibodies
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Immunogen:
Fusion protein amino acids 1019-1293 (cytoplasmic loop between repeat II and repeat III) of human Cav3.2 (also known as Voltage-dependent T-type calcium channel subunit alpha-1H, Low-voltage-activated calcium channel alpha1 3.2 subunit, CACNA1H and Kiaa1120, accession number O95180), epitope mapped to amino acids 1179-1192 (AEDGRAAPGPRATP)
Rat: 77% identity (224/279 amino acids identical), 54% identity for epitope (12/22 amino acids identical), 89% identity for highlighted epitope sequence (8/9 amino acids identical)
Mouse: 77% identity (224/279 amino acids identical), 54% identity for epitope (12/22 amino acids identical), 89% identity for highlighted epitope sequence (8/9 amino acids identical)
Specifications:
Target |
![]() |
Cav3.2 Ca2+ channel |
![]() |
||
Channel Target |
![]() |
Ca2+ Channels |
![]() |
||
Applications |
![]() |
Immunoblot (IB) Immunocytochemistry (ICC) Immunohistochemistry (IHC) Immunoprecipitation (IP) |
![]() |
||
Clone |
![]() |
N55/10 |
![]() |
||
IgG Isotype |
![]() |
IgG1 |
![]() |
||
Species Reactivity |
![]() |
Human (H) Mouse (M) |
![]() |
||
Validation |
![]() |
Br-IHC KO T |
![]() |
||
Type |
![]() |
Purified |
![]() |
||
Format |
![]() |
100 ul |
![]() |
||
Cross Reactivity |
![]() |
Does not cross-react with Cav3.1 |
![]() |
||
Expected Banding Pattern |
![]() |
260 kDa |
![]() |
||
Host |
![]() |
Mouse (M) |
![]() |
||
Label |
![]() |
Unlabeled |
![]() |
||
Antibody Type |
![]() |
Monoclonal |
![]() |
||
Commercial Price |
![]() |
450 |
![]() |
||
Non-Profit Price |
![]() |
200 |
![]() |
||
Distributor Price |
![]() |
Per Contract(QUOTE) |
![]() |
||
ABID |
![]() |
RRID:AB_2315827 |
![]() |
品牌介绍
当抗体公司(Antibodies Incorporated)在1962年开业时,与抗体相关的研究才刚刚开始。创始人Jim Hillman拥有博士学位。从药理学明尼苏达大学,来到加州大学戴维斯分校在免疫化学完整的博士后工作,在工作期间,他学习了加州理工学院(加州理工学院)根据丹·坎贝尔,领域的先驱。吉姆带来了他的妻子,公司的共同创始人卡罗尔(Carol)和两个孩子,以及使用基于抗体的化学疗法寻找治疗癌症的能量和想法。具体地说,吉姆认为,如果他能够识别并分离出可能具有抗原性的肿瘤部位(一个焦点是淋巴肉瘤),则可能有可能进行有效的基于抗体的治疗。吉姆寻找这种治疗方法的梦想推动了他的工作多年。